# OnCo record innocare (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/innocare/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "innocare" ;
  schema:name "InnoCare Pharma"@en ;
  schema:alternateName "诺诚健华"@en ;
  schema:description "InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas."@en ;
  schema:url <https://onco.cc/companies/innocare/>, <https://www.innocarepharma.com/en> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.innocarepharma.com/en> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/orelabrutinib/>, <https://onco.cc/drugs/icp-248/> ;
  onco:trials <https://onco.cc/trials/nct06363994/>, <https://onco.cc/trials/nct04685226/>, <https://onco.cc/trials/nct07617493/>, <https://onco.cc/trials/nct05678270/>, <https://onco.cc/trials/nct05745623/>, <https://onco.cc/trials/nct04014205/>, <https://onco.cc/trials/nct07082686/>, <https://onco.cc/trials/nct06082102/> .